• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

社区教学医院卒中急救流程的治疗效果及结果

Therapeutic yield and outcomes of a community teaching hospital code stroke protocol.

作者信息

Asimos Andrew W, Norton H James, Price Marlow F, Cheek Wilkie M

机构信息

Department of Emergency Medicine, Carolinas Medical Center, PO Box 32861, Charlotte, NC 28232, USA.

出版信息

Acad Emerg Med. 2004 Apr;11(4):361-70. doi: 10.1197/j.aem.2003.12.016.

DOI:10.1197/j.aem.2003.12.016
PMID:15064210
Abstract

OBJECTIVES

To describe the experience of a community teaching hospital emergency department (ED) Code Stroke Protocol (CSP) for identifying acute ischemic stroke (AIS) patients and treating them with tissue plasminogen activator (tPA) and to compare outcome measures with those achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial.

METHODS

This study was a retrospective review from a hospital CSP registry.

RESULTS

Over a 56-month period, CSP activation occurred 255 times, with 24% (n = 60) of patients treated with intravenous (IV) tPA. The most common reasons for thrombolytic therapy exclusion were mild or rapidly improving symptoms in 37% (n = 64), intracerebral hemorrhage (ICH) in 23% (n = 39), and unconfirmed symptom onset time for 14% (n = 24) of patients. Within 36 hours of IV tPA treatment, 10% (NINDS = 6%) of patients (n = 6) sustained a symptomatic ICH (SICH). Three months after IV tPA treatment, 60% of patients had achieved an excellent neurologic outcome, based on a Barthel Index of > or =95 (NINDS = 52%), while mortality measured 12% (NINDS = 17%). Among IV tPA-treated patients, those developing SICH were significantly older and had a significantly higher mean initial glucose value. Treatment protocol violations occurred in 32% of IV tPA-treated patients but were not significantly associated with SICH (Fisher's exact test).

CONCLUSIONS

Over the study period, the CSP yielded approximately one IV tPA-treated patient for every four screened and, despite prevalent protocol violations, attained three-month functional outcomes equal to those achieved in the NINDS trial. For community teaching hospitals, ED-directed CSPs are a feasible and effective means to screen AIS patients for treatment with thrombolysis.

摘要

目的

描述一家社区教学医院急诊科的卒中急救方案(CSP)用于识别急性缺血性卒中(AIS)患者并使用组织纤溶酶原激活剂(tPA)进行治疗的经验,并将结果指标与美国国立神经疾病和卒中研究所(NINDS)试验所取得的结果进行比较。

方法

本研究是对医院CSP登记处进行的回顾性分析。

结果

在56个月的时间里,CSP启动了255次,24%(n = 60)的患者接受了静脉注射(IV)tPA治疗。溶栓治疗排除的最常见原因是症状轻微或迅速改善,占37%(n = 64);脑出血(ICH)占23%(n = 39);14%(n = 24)的患者症状发作时间未得到确认。在静脉注射tPA治疗的36小时内,10%(NINDS为6%)的患者(n = 6)发生了有症状的脑出血(SICH)。静脉注射tPA治疗三个月后,根据巴氏指数≥95,60%的患者获得了良好的神经功能结果(NINDS为52%),而死亡率为12%(NINDS为17%)。在接受静脉注射tPA治疗的患者中,发生SICH的患者年龄明显更大,初始血糖平均值明显更高。32%接受静脉注射tPA治疗的患者出现了治疗方案违规,但与SICH无显著相关性(Fisher精确检验)。

结论

在研究期间,CSP每筛查四名患者约有一名接受静脉注射tPA治疗,尽管普遍存在方案违规情况,但三个月的功能结果与NINDS试验所取得的结果相当。对于社区教学医院而言,急诊科主导的CSP是筛查AIS患者进行溶栓治疗的一种可行且有效的方法。

相似文献

1
Therapeutic yield and outcomes of a community teaching hospital code stroke protocol.社区教学医院卒中急救流程的治疗效果及结果
Acad Emerg Med. 2004 Apr;11(4):361-70. doi: 10.1197/j.aem.2003.12.016.
2
Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.社区医院静脉注射组织型纤溶酶原激活剂治疗前后的方案偏差
J Stroke Cerebrovasc Dis. 2016 Jan;25(1):67-73. doi: 10.1016/j.jstrokecerebrovasdis.2015.08.036. Epub 2015 Sep 26.
3
Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.四所无急性脑卒中团队的急诊科中静脉溶栓的使用安全性。
Acad Emerg Med. 2010 Oct;17(10):1062-71. doi: 10.1111/j.1553-2712.2010.00868.x.
4
Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.电话咨询卒中中心后静脉溶栓的依从性和安全性。
J Stroke Cerebrovasc Dis. 2010 Nov-Dec;19(6):417-23. doi: 10.1016/j.jstrokecerebrovasdis.2009.07.013. Epub 2010 Jun 17.
5
Safety of protocol violations in acute stroke tPA administration.急性卒中 tPA 给药中违反方案的安全性。
J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):855-60. doi: 10.1016/j.jstrokecerebrovasdis.2013.07.019. Epub 2013 Aug 15.
6
Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage.基于社区的重组组织型纤溶酶原激活剂(rTPA)卒中治疗中的方案违规与症状性颅内出血相关。
Stroke. 2001 Jan;32(1):12-6. doi: 10.1161/01.str.32.1.12.
7
Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).血清肌酐可能提示静脉注射组织型纤溶酶原激活剂(IV tPA)后出现症状性颅内出血的风险。
Medicine (Baltimore). 2013 Nov;92(6):317-323. doi: 10.1097/MD.0000000000000006.
8
Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.急性缺血性卒中的质量改进与组织型纤溶酶原激活剂:克利夫兰最新进展
Stroke. 2003 Mar;34(3):799-800. doi: 10.1161/01.STR.0000056944.42686.1E. Epub 2003 Feb 13.
9
Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital.澳大利亚一家三级医院中使用静脉注射组织型纤溶酶原激活剂进行急性中风溶栓治疗。
Med J Aust. 2003 Apr 7;178(7):324-8. doi: 10.5694/j.1326-5377.2003.tb05223.x.
10
Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.低剂量组织型纤溶酶原激活剂治疗急性缺血性卒中:一项系统评价和Meta分析
J Stroke Cerebrovasc Dis. 2018 Feb;27(2):381-390. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.014. Epub 2017 Oct 27.

引用本文的文献

1
Imbalanced Regional Development of Acute Ischemic Stroke Care in Emergency Departments in China.中国急诊科急性缺血性卒中救治的区域发展不均衡
Emerg Med Int. 2019 Aug 6;2019:3747910. doi: 10.1155/2019/3747910. eCollection 2019.
2
Critical Event Intervals in Determining Candidacy for Intravenous Thrombolysis in Acute Stroke.急性卒中静脉溶栓治疗候选资格判定中的关键事件间隔
J Clin Med Res. 2018 Jul;10(7):582-587. doi: 10.14740/jocmr3425w. Epub 2018 Jun 4.
3
The Emergency Care of Patients With Cancer: Setting the Research Agenda.
癌症患者的急诊护理:设定研究议程
Ann Emerg Med. 2016 Dec;68(6):706-711. doi: 10.1016/j.annemergmed.2016.01.021. Epub 2016 Feb 26.
4
The ABCD and ABCD2 Scores and the Risk of Stroke following a TIA: A Narrative Review.ABCD和ABCD2评分与短暂性脑缺血发作后的中风风险:一项叙述性综述。
ISRN Neurol. 2011;2011:518621. doi: 10.5402/2011/518621. Epub 2011 Jul 21.
5
Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.四所无急性脑卒中团队的急诊科中静脉溶栓的使用安全性。
Acad Emerg Med. 2010 Oct;17(10):1062-71. doi: 10.1111/j.1553-2712.2010.00868.x.
6
Determining intravenous rt-PA eligibility in the Emergency Department.在急诊科确定静脉注射重组组织型纤溶酶原激活剂(rt-PA)的适用资格。
Neurocrit Care. 2007;7(2):103-8. doi: 10.1007/s12028-007-0065-1.